WE START THE CONVERSATIONS THAT MATTER
SO OUR CLIENTS CAN CHANGE THE WORLD.

Public and investor relations for the innovators in healthcare and technology

Since our founding in 1988, Russo Partners has been working side by side with innovators and influencers in the healthcare and technology industries. Our evolution in the biopharma and healthcare technology ecosystem is unparalleled as is our network, and the knowledge we bring to our clients is extensive. We bring passion, a culture of excellence, forward thinking and client focus every day to everything we do.

How a Pediatric Robot is Making Education Real for Nursing Students
| RBR

For nursing students at Bunker Hill Community College in Boston, it’s one thing to learn from an instructor or from written material, but it’s far more valuable to interact with a live patient, particularly when it comes to pediatrics, where the patient might not be able to articulate their symptoms as well as an adult […]

read more
Pharvaris – Hereditary Angioedema
| HPR

Berndt Modig, CEO, and Dr. Jochen Knolle, CSO, discuss Pharvaris, a clinical-stage company focused on developing oral therapies for hereditary angioedema (HAE) patients. Hereditary angioedema is a rare and potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people. Current therapies are limited by invasive routes of drug administration (injection or […]

read more
Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 in Patients with Advanced Ovarian Cancer Presented at AACR-NCI-EORTC
| ADC Review

Initial safety data of STRO-002 shows potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models were presented at the AACR-NCI-EORTC.FRα is overexpressed in 80% of ovarian and endometrial carcinoma and shows minimal expression in normal tissues. STRO-002 is a folate receptor alpha (FolRα-) targeting antibody-drug conjugate (ADC) being developed by San Francisco-based Sutro Biopharma […]

read more